What is the recommended apixaban dose for deep‑vein thrombosis prophylaxis in adult patients?

Apixaban Dosing for DVT Prophylaxis

For DVT prophylaxis following hip or knee replacement surgery, apixaban is dosed at 2.5 mg orally twice daily, starting 12-24 hours postoperatively, continued for 35 days after hip replacement or 12 days after knee replacement. 1

Post-Surgical Orthopedic Prophylaxis

Standard prophylactic dosing:

• Dose: 2.5 mg orally twice daily 1
• Timing of first dose: 12-24 hours after surgery 1
• Duration for hip replacement: 35 days (5 weeks) 1
• Duration for knee replacement: 12 days 1

This represents FDA-approved dosing with strong guideline support from multiple societies. 2, 3

Outpatient Medical Prophylaxis in Cancer Patients

For ambulatory cancer patients at high risk of VTE, the ASCO guidelines support apixaban at 2.5 mg orally twice daily for primary prophylaxis. 2 This dosing is consistent across cancer-specific guidelines, though duration beyond 6 months has not been extensively studied in the outpatient prophylaxis setting. 2

Key considerations for cancer patients:

• This dose is specifically for primary prophylaxis in high-risk ambulatory cancer patients 2
• Not all cancer patients require prophylaxis—risk stratification is essential 2
• The Khorana score or other validated tools should guide selection of appropriate candidates 2

Hospitalized Medical Patients

Apixaban is NOT recommended for routine VTE prophylaxis in hospitalized medical patients. 2, 4 A large randomized trial (ADOPT) demonstrated that extended prophylaxis with apixaban 2.5 mg twice daily for 30 days was not superior to short-term enoxaparin and was associated with significantly more major bleeding (relative risk 2.58; 95% CI 1.02-7.24; P=0.04). 4

For hospitalized medical patients, prefer:

• Enoxaparin 40 mg once daily 2
• Dalteparin 5,000 units once daily 2
• Unfractionated heparin 5,000 units every 8 hours 2

Important Distinctions: Prophylaxis vs. Treatment Dosing

Do not confuse prophylactic dosing with treatment dosing:

• Prophylaxis dose: 2.5 mg twice daily 1
• Treatment dose (acute DVT/PE): 10 mg twice daily for 7 days, then 5 mg twice daily 1
• Extended secondary prevention (after ≥6 months treatment): 2.5 mg twice daily 1

The 2.5 mg twice daily dose serves two distinct purposes: primary prophylaxis post-surgery and extended secondary prevention after completing initial VTE treatment—these are different clinical scenarios. 2

Drug Interactions and Dose Adjustments

Avoid apixaban 2.5 mg twice daily in patients taking combined P-glycoprotein AND strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). 1 For patients on higher doses (5 mg or 10 mg twice daily), reduce dose by 50% when these inhibitors are co-administered, but patients already on 2.5 mg twice daily should avoid these combinations entirely. 1

Renal Considerations

For prophylactic dosing (2.5 mg twice daily), no dose adjustment is required for mild to moderate renal impairment. 1 However:

• Use with caution in severe renal impairment (CrCl 15-30 mL/min) 1
• Avoid if CrCl <15 mL/min 2, 1
• Apixaban has only 27% renal clearance, making it more suitable than dabigatran for patients with renal dysfunction 2, 3

Neuraxial Anesthesia Safety

Critical timing considerations for spinal/epidural procedures:

• Discontinue apixaban at least 48 hours before neuraxial anesthesia or procedures with moderate-to-high bleeding risk 1
• Discontinue at least 24 hours before low-bleeding-risk procedures 1
• When transitioning from perioperative LMWH to apixaban, give the first apixaban dose at least 12 hours after the last LMWH dose 3
• The risk of spinal/epidural hematoma is increased with indwelling catheters, concomitant antiplatelet agents, or history of spinal procedures 1

Common Pitfalls to Avoid

Do not use apixaban for:

• Routine prophylaxis in hospitalized medical patients (increased bleeding without efficacy benefit) 2, 4
• Patients with mechanical heart valves (not studied, not indicated) 1
• Active pathological bleeding 1

Do not confuse indications:

• The 2.5 mg twice daily dose for atrial fibrillation requires specific dose-reduction criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL—need 2 of 3 criteria) 1
• These atrial fibrillation dose-reduction criteria do NOT apply to VTE prophylaxis, where 2.5 mg twice daily is the standard dose for all patients 1

Timing matters:

• Starting too early postoperatively increases bleeding risk 1
• The 12-24 hour window after surgery represents the optimal balance between thrombosis prevention and hemostasis 1